Damon L Bass (Damon Bass)

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 3

Top Topics

Replacement Therapy

Systemic Lupus Erythematosus

Disease Activity

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Fengchun Zhang, Jie Zheng, Yang Li, Guochun Wang, Mingjun Wang, Yin Su, Jieruo Gu, Xingfu Li, Damon L Bass, Myron Chu, Paula Curtis, Kathleen DeRose, Regina Kurrasch, Jenny Lowe, Paige Meizlik, David A Roth
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years. RMD open 8 (1) (2022)
Hermine I Brunner, Carlos Abud Mendoza, Masaaki Mori, Clarissa A Pilkington, Reema Syed, Syuji Takei, Diego O Viola, Richard A Furie, Sandra V Navarra, Fengchun Zhang, Damon L Bass, Gina Eriksson, Anne E Hammer, Beulah N Ji, Mohamed Okily, David A Roth, Holly A Quasny, Nicolino Ruperto
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD open 7 (3) (2021)
Yoshiya Tanaka, Sang-Cheol Bae, Damon L Bass, Paula Curtis, Myron Chu, Kathleen DeRose, Beulah N Ji, Regina Kurrasch, Jenny Lowe, Paige Meizlik, David A Roth
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. RMD open 7 (2) (2021)